依赖糖皮质激素的哮喘患者死亡率增加:一项全国性人群研究
该研究基于韩国国民健康保险服务数据库(2005—2015年),纳入466 941例成人哮喘患者,其中8334例为依赖系统性糖皮质激素(CS)者。经1:1匹配后,CS依赖组相对非依赖组的全因死亡风险比为2.17(95%CI 2.04–2.31),低剂量组HR为1.84(95%CI 1.69–2.00),高剂量组HR为2.56(95%CI 2.35–2.80),呈现显著剂量-反应关系。
要点
- 长期使用系统性糖皮质激素的哮喘患者全因死亡风险约为非依赖者的2.17倍。
- 死亡风险随激素剂量增加而升高,高剂量组HR达2.56。
- 临床应重视CS依赖型哮喘患者的死亡风险评估与激素减量策略。
核心结论
- 长期系统性糖皮质激素使用与哮喘患者全因死亡风险增加相关,且存在显著剂量-反应关系。
研究设计与样本
- 基于韩国国民健康保险服务数据库(2005—2015年)的全国性人群匹配队列研究,纳入≥18岁哮喘患者466 941例,其中CS依赖组8334例、非依赖组458 607例,经1:1匹配后各8334例。
主要发现
- CS依赖组相对非依赖组的全因死亡HR为2.17(95%CI 2.04–2.31)。
- 低剂量CS组死亡HR为1.84(95%CI 1.69–2.00)。
- 高剂量CS组死亡HR为2.56(95%CI 2.35–2.80)。
关键数值与推荐
- CS依赖定义为基线期系统性糖皮质激素使用≥6个月,非依赖定义为使用<6个月。
临床怎么用
- 对依赖系统性糖皮质激素的哮喘患者应加强死亡风险评估,并审慎优化激素用量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Chronic systemic corticosteroid (CS) therapy is associated with an increased risk of mortality in patients with many chronic diseases. However, it has not been elucidated whether chronic systemic CS therapy is associated with increased mortality in patients with asthma. The aim of this study was to determine the effects of chronic systemic CS therapy on long-term mortality in adult patients with asthma. METHODS: A population-based matched cohort study of males and females aged ≥18 years with asthma was performed using the Korean National Health Insurance Service database from 2005 to 2015. Hazard ratio (HR) with 95% confidence interval for all-cause mortality among patients in the CS-dependent cohort (CS use ≥6 months during baseline period) relative to those in the CS-independent cohort (CS use <6 months during baseline period) was evaluated. RESULTS: The baseline cohort included 466 941 patients with asthma, of whom 8334 were CS-dependent and 458 607 were CS-independent. After 1:1 matching, 8334 subjects with CS-independent asthma were identified. The HR of mortality associated with CS-dependent asthma relative to CS-independent asthma was 2.17 (95% CI 2.04-2.31). In patients receiving low-dose CS, the HR was 1.84 (95% CI 1.69-2.00); in patients receiving high-dose CS, the HR was 2.56 (95% CI 2.35-2.80). CONCLUSIONS: In this real-world, clinical practice, observational study, chronic use of systemic CS was associated with increased risk of mortality in patients with asthma, with a significant dose-response relationship between systemic CS use and long-term mortality.
引用
- Lee H, Ryu J, Nam E, et al. Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study. Eur Respir J. 2019. PMID: 31515404. doi:10.1183/13993003.00804-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。